Literature DB >> 12610751

Raynaud's phenomenon induced by drugs acting on neurotransmission: two cases under reboxetine and one under tegaserod.

Raffaela Bertoli1, François Girardin, Stefan Russmann, Bernhard H Lauterburg.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12610751     DOI: 10.1007/s00228-002-0552-4

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  4 in total

Review 1.  Raynaud's phenomenon.

Authors:  J A Block; W Sequeira
Journal:  Lancet       Date:  2001-06-23       Impact factor: 79.321

2.  Fluoxetine-induced Raynaud's phenomenon.

Authors:  A Rudnick; I Modai; A Zelikovski
Journal:  Biol Psychiatry       Date:  1997-06-15       Impact factor: 13.382

3.  The effects of reboxetine on autonomic and cognitive functions in healthy volunteers.

Authors:  M Siepmann; M Mück-Weymann; P Joraschky; W Kirch
Journal:  Psychopharmacology (Berl)       Date:  2001-09       Impact factor: 4.530

4.  Blockade of vasospastic attacks by alpha 2-adrenergic but not alpha 1-adrenergic antagonists in idiopathic Raynaud's disease.

Authors:  R R Freedman; R P Baer; M D Mayes
Journal:  Circulation       Date:  1995-09-15       Impact factor: 29.690

  4 in total
  3 in total

Review 1.  Drug-induced Raynaud's phenomenon: beyond β-adrenoceptor blockers.

Authors:  Charles Khouri; Sophie Blaise; Patrick Carpentier; Céline Villier; Jean-Luc Cracowski; Matthieu Roustit
Journal:  Br J Clin Pharmacol       Date:  2016-04-07       Impact factor: 4.335

Review 2.  Advances in the treatment of Raynaud's phenomenon.

Authors:  Terri L Levien
Journal:  Vasc Health Risk Manag       Date:  2010-03-24

3.  Treatment Options for Primary Constipation.

Authors:  Vijayamalini Pampati; Ronald Fogel
Journal:  Curr Treat Options Gastroenterol       Date:  2004-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.